Your browser doesn't support javascript.
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres

Base de données
Année
Type de document
Gamme d'année
1.
PLoS One ; 17(2): e0253638, 2022.
Article Dans Anglais | MEDLINE | ID: covidwho-1910476

Résumé

Population immunity (herd immunity) to SARS-CoV-2 derives from two sources: vaccinations or cases of infection with the virus. Infections can be diagnosed as COVID-19 and registered, or they can be asymptomatic, oligosymptomatic, or even full-blown but undiagnosed and unregistered when patients recovered at home. Estimation of population immunity to SARS-CoV-2 is difficult and remains a subject of speculations. Here we present a population screening for SARS-CoV-2 specific IgG and IgA antibodies in Polish citizens (N = 501) who had never been positively diagnosed with or vaccinated against SARS-CoV-2. Serum samples were collected in Wroclaw (Lower Silesia) on 15th and 22nd May 2021. Sera from hospitalized COVID-19 patients (N = 22) or from vaccinated citizens (N = 14) served as positive controls. Sera were tested with Microblot-Array COVID-19 IgG and IgA (quantitative) that contain specific SARS-CoV-2 antigens: NCP, RBD, Spike S2, E, ACE2, PLPro protein, and antigens for exclusion cross-reactivity with other coronaviruses: MERS-CoV, SARS-CoV, HCoV 229E Np, HCoV NL63 Np. Within the investigated population of healthy individuals who had never been positively diagnosed with or vaccinated against SARS-CoV-2, we found that 35.5% (178 out of 501) were positive for SARS-CoV-2-specific IgG and 52.3% (262 out of 501) were positive for SARS-CoV-2-specific IgA; 21.2% of the investigated population developed virus-specific IgG or IgA while being asymptomatic. Anti-RBD IgG, which represents virus-neutralizing potential, was found in 25.6% of individuals (128 out of 501). These patients, though positive for anti-SARS-CoV-2 antibodies, cannot be identified in the public health system as convalescents due to undiagnosed infections, and they are considered unaffected by SARS-CoV-2. Their contribution to population immunity against COVID-19 should however be considered in predictions and modeling of the COVID-19 pandemic. Of note, the majority of the investigated population still lacked anti-RBD IgG protection (74.4%); thus vaccination against COVID-19 is still of the most importance for controlling the pandemic.


Sujets)
Infections asymptomatiques/épidémiologie , Vaccins contre la COVID-19/usage thérapeutique , COVID-19/épidémiologie , COVID-19/immunologie , Immunité de groupe , Pandémies/prévention et contrôle , SARS-CoV-2/immunologie , Vaccination/méthodes , Adolescent , Adulte , Sujet âgé , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Antigènes viraux/immunologie , COVID-19/sang , COVID-19/prévention et contrôle , Réactions croisées , Femelle , Humains , Immunoglobuline A/sang , Immunoglobuline A/immunologie , Immunoglobuline G/sang , Immunoglobuline G/immunologie , Mâle , Adulte d'âge moyen , Pologne/épidémiologie , Résultat thérapeutique , Jeune adulte
SÉLECTION CITATIONS
Détails de la recherche